/Insulet%20Corporation%20logo%20on%20phone-by%20rafapress%20via%20Shutterstock.jpg)
Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued at $20.2 billion by market cap, the company develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The insulin infusion systems maker is expected to announce its fiscal second-quarter earnings for 2025 before the market opens on Thursday, Aug. 7.
Ahead of the event, analysts expect PODD to report a profit of $0.93 per share on a diluted basis, up 69.1% from $0.55 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.
